A low dose lipid infusion is sufficient to induce insulin resistance and a pro-inflammatory response in human subjects
Open Access
- 12 April 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (4) , e0195810
Abstract
The root cause behind the low-grade inflammatory state seen in insulin resistant (obesity and type 2 diabetes) states is unclear. Insulin resistant subjects have elevations in plasma free fatty acids (FFA), which are ligands for the pro-inflammatory toll-like receptor (TLR)4 pathway. We tested the hypothesis that an experimental elevation in plasma FFA (within physiological levels) in lean individuals would upregulate TLR4 and activate downstream pathways (e.g., MAPK) in circulating monocytes. Twelve lean, normal glucose-tolerant subjects received a low dose (30 ml/h) 48 h lipid or saline infusion on two different occasions. Monocyte TLR4 protein level, MAPK phosphorylation, and expression of genes in the TLR pathway were determined before and after each infusion. The lipid infusion significantly increased monocyte TLR4 protein and phosphorylation of JNK and p38 MAPK. Lipid-mediated increases in TLR4 and p38 phosphorylation directly correlated with reduced peripheral insulin sensitivity (M value). Lipid increased levels of multiple genes linked to inflammation, including several TLRs, CD180, MAP3K7, and CXCL10. Monocytes exposed in vivo to lipid infusion exhibited enhanced in vitro basal and LPS-stimulated IL-1β secretion. In lean subjects, a small increase in plasma FFA (as seen in insulin resistant subjects) is sufficient to upregulate TLR4 and stimulate inflammatory pathways (MAPK) in monocytes. Moreover, lipids prime monocytes to endotoxin. We provide proof-of-concept data in humans indicating that the low-grade inflammatory state characteristic of obesity and type 2 diabetes could be caused (at least partially) by pro-inflammatory monocytes activated by excess lipids present in these individuals.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK80157)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK089229)
- CTSA (UL1TR001120)
- NIH/NIA (P30 AG044271)
- ADA: GlaxoSmithKline (7-13-GSK-01)
This publication has 36 references indexed in Scilit:
- Effect of Lipopolysaccharide on Inflammation and Insulin Action in Human MusclePLOS ONE, 2013
- Short-Term Exercise Training Improves Insulin Sensitivity but Does Not Inhibit Inflammatory Pathways in Immune Cells from Insulin-Resistant SubjectsJournal of Diabetes Research, 2013
- TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipidinduced inflammation and insulin resistance in muscle cellsBioscience Reports, 2012
- Endotoxin increase after fat overload is related to postprandial hypertriglyceridemia in morbidly obese patientsJournal of Lipid Research, 2012
- Monocyte and Macrophage Dynamics During AtherogenesisArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Increased Toll-Like Receptor (TLR) Activation and TLR Ligands in Recently Diagnosed Type 2 Diabetic SubjectsDiabetes Care, 2010
- Increase in Plasma Endotoxin Concentrations and the Expression of Toll-Like Receptors and Suppressor of Cytokine Signaling-3 in Mononuclear Cells After a High-Fat, High-Carbohydrate MealDiabetes Care, 2009
- Phenotypic Switching of Adipose Tissue Macrophages With Obesity Is Generated by Spatiotemporal Differences in Macrophage SubtypesDiabetes, 2008
- Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant SubjectsDiabetes, 2008
- TLR4 links innate immunity and fatty acid–induced insulin resistanceJournal of Clinical Investigation, 2006